Supha Pharmachem Enters Insolvency Over Rs 7.47 Crore Default

Introduction

Supha Pharmachem Limited, formerly known as Remedium Lifecare Limited, has been admitted into the Corporate Insolvency Resolution Process (CIRP) by the Mumbai bench of the National Company Law Tribunal (NCLT). The order, dated March 17, 2026, follows a petition filed by an operational creditor, Boston Ivy Healthcare Solution Private Limited, citing a default of approximately Rs 7.47 crore. This development places the pharmaceutical company under the purview of the Insolvency and Bankruptcy Code (IBC), 2016, leading to a suspension of its board and the imposition of a moratorium.

The Insolvency Petition

The NCLT admitted the petition, C.P. (IB) No. 579/MB/2025, under Section 9 of the IBC, which allows operational creditors to initiate insolvency proceedings against a corporate debtor. The petitioner, Boston Ivy Healthcare Solution Private Limited, claimed a default amounting to Rs. 7,47,20,079, including interest. The date of the default is cited as November 7, 2023. The tribunal's decision to initiate CIRP marks the formal commencement of a process aimed at resolving the company's financial distress.

Appointment of Interim Resolution Professional

With the admission of the insolvency plea, the NCLT has appointed Mr. Rajesh Jhunjhunwala as the Interim Resolution Professional (IRP) to oversee the proceedings. As the IRP, Mr. Jhunjhunwala will take control of the company's management and operations. His primary responsibilities include making a public announcement of the CIRP initiation and inviting claims from all creditors of Supha Pharmachem. The management of the company's assets and affairs now rests entirely with the IRP for the duration of the process.

Moratorium and Suspension of the Board

Effective immediately from March 17, 2026, a moratorium under Section 14 of the IBC has been imposed on Supha Pharmachem. This legal measure provides a crucial 'calm period' by prohibiting several actions against the company. These restrictions include:

• The institution or continuation of lawsuits or legal proceedings.
• The transfer, encumbrance, or disposal of any of its assets.
• Any action to foreclose, recover, or enforce any security interest.

In conjunction with the moratorium, the powers of the company's Board of Directors have been suspended as per Section 17 of the IBC. All directorial and management powers are now vested in the IRP, who will act to preserve the value of the company's assets during the resolution period.

A Period of Significant Corporate Change

The insolvency proceedings come at a time of significant transition for the company. It was only on December 15, 2025, that Remedium Lifecare Limited was officially renamed Supha Pharmachem Limited, a move approved by over 97% of its shareholders. Coincidentally, on the same day the NCLT passed its insolvency order, March 17, 2026, the company's board had approved the relocation of its registered office from Marol, Andheri East, to Goregaon East in Mumbai. These recent changes paint a picture of a company undergoing major restructuring just as it faced this critical financial challenge.

Financial Health and Stock Performance

A review of the company's financial indicators and market performance provides context for its current situation. The stock has seen a significant decline over the past year, reflecting underlying financial pressures. The insolvency admission follows a period of poor market sentiment and operational difficulties that culminated in the default.

This performance contrasts sharply with optimistic announcements from mid-2025, including a growth strategy and strong quarterly results, highlighting a rapid deterioration in its financial stability leading to the default.

Path Forward

With the CIRP now underway, the future of Supha Pharmachem Limited depends on the resolution plan that will be formulated and presented to the Committee of Creditors (CoC). The IRP will first collate all claims and form the CoC, which will then guide the resolution process. Stakeholders, including creditors, employees, and shareholders, will be closely watching the proceedings to determine the company's viability and potential for revival under the IBC framework.